EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Regencell Bioscience Holdings's Enterprise Value is $72.70 Mil.
Regencell Bioscience Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Regencell Bioscience Holdings's EV-to-FCF for today is .
The historical rank and industry rank for Regencell Bioscience Holdings's EV-to-FCF or its related term are showing as below:
RGC'
s EV-to-FCF Range Over the Past 10 Years
Min: -680.97 Med: 0 Max: 0
Current: -14.57
RGC's EV-to-FCF is ranked worse than 100% of 513
companies
in the Drug Manufacturers industry
Industry Median: 21.66
vs RGC: -14.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Regencell Bioscience Holdings's stock price is $5.70.
Regencell Bioscience Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.450. Therefore, Regencell Bioscience Holdings's PE Ratio for today is At Loss.
Regencell Bioscience Holdings EV-to-FCF Historical Data
The historical data trend for Regencell Bioscience Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings EV-to-FCF Distribution
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's EV-to-FCF falls into.
Regencell Bioscience Holdings's current Enterprise Value is $72.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Regencell Bioscience Holdings's PE Ratio for today is calculated as:
Regencell Bioscience Holdings's share price for today is $5.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Regencell Bioscience Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.450.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Regencell Bioscience Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGC has been successfully added to your 